Histogen, Inc.

67 articles with Histogen, Inc.

• Histogen Appoints Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations

  10/19/2020

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced the appointment of Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations. “I am pleased to have Moya join the Histogen team at this important time as we continue

• Histogen Announces Completion of Final Dosing Timepoint Milestone in its 1b/2a Trial for Androgenic Alopecia in MenTop Line Results Remain on Track for Q4’2020

  10/5/2020

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced completion of patient dosing in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.

• Histogen Announces Update for its HST-002 Dermal Filler Program

  9/29/2020

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that it received communications from the Office of Combination Products (OCM), a division of the United States Food and Drug Administration (FDA), t

• Histogen Announces $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee

  9/16/2020

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, has been awarded a $2 million grant by the Peer Reviewed Orthopedic Research Program (PRORP) of the U.S. Department of Defense (DoD) to help fund a Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee.

• Histogen Announces Completion of Dosing Milestone in its 1b/2a Trial for Androgenic Alopecia in MenTop Line Results Remain on Track for Q4’2020

  9/10/2020

  Histogen Inc. (NASDAQ: HSTO),  a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced completion of patient dosing for the week 6 treatment timepoint in its Phase 1b/2a clinical trial of HST-001,

• Histogen to Present at the HC Wainwright 22nd Annual Global Investment Conference

  9/1/2020

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the HC Wainwright 22nd Annual Global Investment Conference. 

• Histogen Reports Second Quarter 2020 Earnings and Provides Business Update

  8/13/2020

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today reported financial results for the second quarter ended June 30, 2020 a

• Histogen to Report Second Quarter 2020 Earnings on August 13, 2020

  7/30/2020

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the second quarter ended June 30, 2020

• Histogen to Present at the Canaccord Genuity 40th Annual Growth Conference

  7/29/2020

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the Canaccord Genuity 40th Annual Growth Conference

• Histogen Inc. Announces Common Stock Purchase Agreement for up to $10 Million with Lincoln Park Capital Fund, LLCIncludes an Initial Investment of $1 Million

  7/20/2020

  Histogen Inc. (“Histogen” or the “Company”) (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced that it has that it has entered into a common stock purchase agreement for up to $10 million with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a Chicago-based institutional investor. Upon execution of the purchase agreement, Lincoln Park made an initial pur

• Histogen Announces Completion of Patient Enrollment for its HST 001 Phase 1b/2a Trial for Androgenic Alopecia in MenTop Line Results Expected Q4’2020

  7/14/2020

  Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced completion of patient enrollment ahead of schedule in its Phase 1b/2a clinical trial of HST 001, designed to assess the safety, tolerability and indicators of efficacy of HST 001 for the treatment of androgenic alopecia in men.

• Histogen to Present at BIO Digital 2020

  6/3/2020

  Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it will be featured as a presenting company at BIO Digital 2020, being held virtually June 8-12, 2020. In addition to completion of its merger with Conatus Pharmaceuticals in May 2020, enrollment is currently underway in Histogen’s Phase 1b/2a clinical trial of its lead product candi

• Histogen Announces First Patient Dosed in Phase 1b/2a Trial of HST 001 for Androgenic AlopeciaTop-Line Data Expected in Q4 2020

  6/1/2020

  Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the enrollment of the first patient in its Phase 1b/2a clinical trial of HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men. This blinded, randomized, placebo controlled, single site study will enroll 36 subjects with male pattern hair loss u

• Histogen Appoints Susan A. Knudson as Chief Financial Officer

  5/28/2020

  Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced the appointment of Susan A. Knudson as Executive Vice President and Chief Financial Officer.

• Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals

  5/27/2020

  Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced the completion of its previously disclosed merger with Conatus Pharmaceuticals Inc.

• Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split

  5/18/2020

  Conatus Pharmaceuticals Inc. announced that Institutional Shareholder Services Inc. and Glass Lewis, have recommended that Conatus stockholders vote “FOR” Conatus’ proposed merger with Histogen Inc. and “FOR” Conatus’ proposed reverse stock split, both of which are to be considered at Conatus’ upcoming special meeting of stockholders to be held on May 21, 2020.

• Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

  5/14/2020

  Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair in the Journal of Medicine and Surgical Sciences. Histogen has developed a cell conditioned media (CCM) that is embryonic-like in composition and that has been shown to stimulate stem cells in vivo. The ma

• Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia

  5/11/2020

  Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration has approved its Investigational New Drug application for HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men.

• The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020

  5/7/2020

  Conatus Pharmaceuticals Inc. convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockholder approvals required pursuant to the terms of its merger agreement with Histogen Inc.

• Histogen Announces Investigational Device Exemption Application for HST 002

  4/20/2020

  Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it has submitted an Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of HST 002 for the treatment of facial folds and wrinkles.